Thursday, January 20, 2022 Daily Archives

In brief: Vetter opens clinical filling site in Austria

by

Vetter has received manufacturing authorization for a fill and finish site Austria, which the CDMO acquired in 2020. Contract development and manufacturing organization (CDMO) Vetter bought the clinical production site in Rankweil, on the Austrian border with Switzerland and Liechenstein, from Impletio – part of Rentschler, with which Vetter inked an alliance in July 2020. The firm has been working to modify and equip all laboratory, technical and production areas at the 10,000 square-meter facility and has announced this week…

January 20, 2022

HPNE to expand single-use capacity on back of $15m BARDA contract

by

Funding from BARDA gives High Purity New England (HPNE) the opportunity to expand into its fourth facility, the bioprocess vendor says. HPNE has been contracted to produce pharmaceutical consumable equipment for the Biomedical Advanced Research and Development Authority (BARDA) and its third parties, issued in response to a Presidential Declaration of Public Health Emergency. The $15 million contract – number 75A50122C00009 – forms part of the office of the Assistant Secretary for Preparedness and Response at the US Department of…

January 20, 2022

Novo Nordisk Foundation invests $343m to build stem-cell research center

by

Novo Nordisk Foundation will invest up to $343 million over a ten-year period to establish an international research center focused on stem cell medicine. The center is a partnership entitled reNEW between the University of Copenhagen, Denmark, Murdoch Children’s Research Institute, Australia, and Leiden University Medical Center, The Netherlands. The aim of the collaboration is to drive future stem cell-based treatments. The governing hub will be based at the Faculty of Health and Medical Sciences, University of Copenhagen and Melissa…

January 20, 2022

CBM and UPenn enter gene therapy manufacturing pact

by

A five-year deal will see the Center for Breakthrough Medicines (CBM) gain commercial rights to certain gene therapy manufacturing and analytics platforms from the University of Pennsylvania. The King of Prussia, Pennsylvania-based contract development and manufacturing organization (CDMO) has entered a collaboration with the University of Pennsylvania Gene Therapy Program (GTP) to help small biotech firms, universities, and large pharma firms advance gene therapies through the clinic. The collaboration brings CBM access to UPenn’s gene therapy expertise, which has helped…

January 20, 2022